Your Team for Swiss Law – now also in Geneva

Search filters

T3 Pharmaceuticals AG closes its second financing round

T3 Pharmaceuticals AG, a Basel-based company focusing on immuno-oncology, closes its second financing round of over 12M CHF with existing investors joined by Boehringer Ingelheim Venture Fund (BIVF) and Reference Capital SA.

VISC...

KLV Verlag AG sold to Westermann Group

KLV Verlag AG in St. Gallen, specialising in teaching materials, workbooks and non-fiction books for vocational training for vocational schools and grammar schools, will be sold retroactively as of January 1, 2019, to the...

ALENTIS Therapeutics raises CHF 12.5m in Series A Financing

ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5 million. ALENTIS’ lead program is a...

Cooperation between Spaeter/RUWA and Peikko

Spaeter AG, based in Basel, a Swiss wholesaler in the construction and ancillary construction sector, and its subsidiary RUWA-Drahtschweisswerk AG have entered into a comprehensive cooperation in Switzerland with the Finnish...

Anaveon closes CHF 35 m Series A financing

Anaveon, an immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with financing from BaseLaunch,...

Oculis in-licenses novel phase II-stage Anti-TNF alpha antibody fragment

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis. The...

AC Immune and Lilly announce license and collaboration agreement

AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE:LLY) have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s...

Azafaros B.V. gets seed funding

Azafaros (www.azafaros.com), a biotech company established in Leiden in the Netherlands, focusing on the development of new therapies in the field of rare metabolic disorders, announced the closing of a seed financing round....

Series A Financing Round of aktiia SA

TransLink Capital, a leading US venture capital fund, has invested as lead investor in the Series A financing round of aktiia SA, Neuchâtel, a Swiss startup active in optical blood pressure monitoring.  VISCHER advised TransLink...

AC Immune issues up to 10 Million Common Shares

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, issues up to 10 million new common shares at a price of USD 11.75 per share. This offering price will be...

You are currently offline. Some pages or content may fail to load.